Chris Fox
@ProfChrisPFox
Followers
1K
Following
1K
Media
28
Statuses
670
Professor of Haematology & lymphoma-ologist, University of Nottingham. Chair, UK high-grade lymphoma study group. (no med advice)
United Kingdom
Joined July 2019
RT @CureLeukaemia: As they begin the defence of their Euro title, ever wanted to play alongside some former #Lionesses?. Join us for Copa D….
0
1
0
RT @DrRaulCordoba: #Hematology Allogeneic haematopoietic cell transplantation in peripheral T-cell #lymphoma #PTCL: recommendations from th….
0
7
0
RT @graham74GC: It’s back and it’s online. The fantastic #lymphomaManagement course. With much thanks to @LymphomaAction for their suppor….
0
7
0
RT @Mc73James: Run the Nations Update - here are the days, mileage and timings. Looking for people to run part / all of a stage with me ,….
0
3
0
Big thanks to a great team behind this novel & ambitious study.@Jessica_Okosun @CwynKate @graham_mcilroy @MartinezCalleMD #jeffsmith #bethphilips et al @CRCTU_Haem_Team @CRCTU #TAPnetwork @act4patients @CureLeukaemia @BloodCancer_Res.
At #18ICML, @ProfChrisPFox of @nottmhospitals shared the results of cohort one of the PRiZM+ platform study, in which patients with R/R primary CNS #lymphoma were treated with zanubrutinib monotherapy.🩸. Watch here:.🎥 #LYMsm #CTSM #HemOnc #ICML2025.
0
2
14
RT @NICEComms: Around 250 people with mantle cell lymphoma will benefit from NICE's recommendation of zanubrutinib (Brukinsa), providing an….
0
8
0
RT @lymphomahub: CONGRESS | #18ICML | PRESENTATION.Christopher Fox @ProfChrisPFox @UniofNottingham presents results from Cohort 1 of the ph….
0
11
0
RT @VJHemOnc: Thank you @ProfChrisPFox for popping by and sharing insights into a cohort from the Phase II PRiZM+ platform study, evaluatin….
0
1
0
RT @tobyeyre82: ➡️➡️Big CLL news!.Munir et al.OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL #EHA2025.Congrats to all FLAIR tr….
0
37
0
…and published today in NEJM .
CONGRESS | #EHA2025 | PRESENTATION Talha Munir, @Leeds_Cancer, shares findings from the FLAIR study of MRD-guided Ibr+Ven vs Ibr monotherapy vs FCR in CLL (N=786). Ibr+Ven demonstrated superiority of PFS (93.9% vs 58.1% vs 79.0%) and OS (95.9% vs 86.5% vs 90.5%) compared to FCR
0
1
23
RT @BloodCancer_Res: 🚨 New grants for healthcare professionals!. We’re looking to fund projects that aim to make clinical trials more acces….
0
10
0
RT @lymphomahub: CONGRESS | #ASCO25 | PRESENTATION.Jeremy Abramson, @MassGeneralNews, shares 2-year data from STARGLO trial of Glofit-GemOx….
0
7
0
RT @bloodcancer_uk: 280,000 in the UK are living with, or are in remission from leukaemia, lymphoma, myeloma, MPN or MDS. Yet all too ofte….
0
105
0
RT @BritSocHaem: We have a new guideline!. Take a look at the Management of relapsed or refractory large B-cell lymphoma here: . https://t.c….
0
4
0
RT @CureLeukaemia: Hear from Dr. Pramila Krishnamurthy at King’s College Hospital as she explains the crucial role of clinical trials in ad….
0
4
0
RT @BrJHaem: 🚨 Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline . Full text here: ht….
0
47
0
RT @SridharChaganti: Just released BSH R/R LBCL guideline with updated guidance on this rapidly evolving field.
0
12
0
RT @tobyeyre82: So much change in R/R #DLBCL over recent years!.See the updated @BritSocHaem guidelines now online. .
0
30
0
Great study @LeppaSM - congratulations on delivering these important data!. Strongly supports a biologically-risk-stratified study. Now we have more effective therapies to intervene with. Time to be RAdICAL? .Watch this space 🇬🇧.
Happy to share the results of the Nordic biomarker-adapted trial in patients with high-risk LBCL (NLG-LBC-06) just released online in @Hemasphere_EHA at.We learned that prospective stratification according to biological risk factors is feasible.
1
1
3
RT @CureLeukaemia: Caroline was recruited onto the international OptiMATe trial and shares the vital role clinical trials played in her jou….
0
1
0